CD34 and myelofibrosis: Passamonti et al. reported that JAK2V617F mutation activates granulocytes and mobilizes CD34 cells, and that the transition of JAK2V617F from heterozygosity to homozygosity could play a role in the progression of PV to post-PV myelofibrosis;[9] however, this has not yet been confirmed.